Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
|
|
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/17/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Issue Date: September 8, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms use...",
"COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: _______ Initial Exercise Date: September 8, 2022 Issue Date: September 8, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 8, 2022 and on or prior to 5:00 p.m. on September 8, 2027 but not thereafter, to subscribe for and purchase from Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation , up to ______ shares of common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Defi...",
" ",
"SECURITIES PURCHASE AGREEMENT",
"SECURITIES PURCHASE AGREEMENT",
" ",
" " |
|
| 08/15/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 03/15/2022 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 02/01/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 12/10/2021 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Quarterly results |
| 09/20/2021 |
8-K
| Quarterly results |
| 08/16/2021 |
8-K
| Quarterly results |
| 06/16/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
8-K
| Results of Operations and Financial Condition |
| 05/07/2021 |
8-K
| Results of Operations and Financial Condition, Non-Reliance on Previously Issued Financial Statements or a Related Audit Repo... |
| 04/15/2021 |
8-K
| Quarterly results |
| 03/22/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/04/2021 |
8-K
| Quarterly results |
| 01/20/2021 |
8-K/A
| Changes in Registrant's Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Fina... |
| 12/18/2020 |
8-K
| Director compensation was amended/approved|
Docs:
|
"Certificate of Corporate Domestication",
"Amended and Restated Certificate of Incorporation",
"Form of Assumed Warrant",
"Employment Agreement, by and between the Company and Dr. Bhat",
"Offer of Employment, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Letter Agreement, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Letter Agreement, by and between Marc Cantillon, MD and Reviva Pharmaceuticals, Inc",
"Form of Indemnification Agreement",
"Saxena Indemnification Agreement",
"Form of Non-Redemption Agreement, by and among the Company, Tenzing LLC and the shareholder party thereto" |
|
| 12/14/2020 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 12/09/2020 |
8-K
| Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders |
| 11/19/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/13/2020 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ... |
|
|
|